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14 Abstract Administration of the long form (38 amino acids)
15 of pituitary adenylate cyclase-activating polypeptide
16 (PACAP38) into the central nervous system causes hyperther-
17 mia, suggesting that PACAP38 plays a role in the regulation of
18 deep body temperature (Tb). In this study, we investigated the
19 thermoregulatory role of PACAP38 in details. First, we in-
20 fused PACAP38 intracerebroventricularly to rats and mea-
21 sured their Tb and autonomic thermoeffector responses. We
22 found that central PACAP38 infusion caused dose-dependent
23 hyperthermia, which was brought about by increased thermo-
24 genesis and tail skin vasoconstriction. Compared to intra-
25 cerebroventricular administration, systemic (intravenous) in-
26 fusion of the same dose of PACAP38 caused significantly
27 smaller hyperthermia, indicating a central site of action. We
28 then investigated the thermoregulatory phenotype of mice
29 lacking the Pacap gene (Pacap−/−). Freely moving Pacap−/−
30 mice had higher locomotor activity throughout the day and
31 elevated deep Tb during the light phase. When the Pacap
−/−
32 mice were loosely restrained, their metabolic rate and Tb were
33 lower compared to their wild-type littermates. We conclude
34that PACAP38 causes hyperthermia via activation of the au-
35tonomic cold-defense thermoeffectors through central targets.
36Pacap−/− mice express hyperkinesis, which is presumably a
37compensatory mechanism, because under restrained condi-
38tions, these mice are hypometabolic and hypothermic com-
39pared to controls.
40Keywords PACAP . Hyperthermia . Thermoregulation .
41Locomotor activity . Autonomic thermoeffectors
42Introduction
43The long form of the pituitary adenylate cyclase-activating
44polypeptide (PACAP) consists of 38 amino acids (PACAP38),
45and together with its receptors (PAC1 and VPAC1/2 recep-
46tors), it is widely expressed both in peripheral organs and in
47the central nervous system (CNS), explaining its diverse bio-
48logical functions (for review, see Vaudry et al. 2009). Of note,
49a shorter form of the peptide (PACAP27) has also been
50identified (Miyata et al. 1990), but since in most tissues
51PACAP38 is the predominant form with a concentration ratio
52of PACAP27:PACAP38 to <1:9 (Vaudry et al. 2000, 2009)
53and because the effects of the PACAP27 and PACAP38 on
54cAMP formation (Nowak and Kuba 2002), vascular responses
55(Lenti et al. 2007), and on body temperature (Seeliger et al.
562010) are similar, the current study focused on the effects of
57PACAP38. In the CNS, PACAP exerts neurotrophic effects
58(Vaudry et al. 1999; Njaine et al. 2014) as well as neuropro-
59tective actions in experimental models of local ischemia
60(Reglodi et al. 2000; Danyadi et al. 2014), Parkinson’s disease
61(Brown et al. 2013, 2014) and viral neurotoxicity (Rozzi et al.
622014). The peptide is known to regulate pituitary hormone
63secretion (Koves et al. 2014) and improve barrier properties of
64the endothelial cells in the brain (Wilhelm et al. 2014). On the
65periphery, PACAP has been shown to have an anti-
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66 inflammatory role in diabetic kidney damage (Banki et al.
67 2013, 2014), neurogenic inflammation (Helyes et al. 2007),
68 and contact dermatitis (Kemeny et al. 2010). PACAP has been
69 reported to play an important role in the regulation of numer-
70 ous homeostatic processes by influencing circadian rhythm
71 (Nagy and Csernus 2007; Racz et al. 2008) and food intake
72 (Hawke et al. 2009; Resch et al. 2011). Since the isolation of
73 PACAP38 by Miyata et al. (1989), a large number of studies
74 have been conducted to identify the role of the peptide in
75 various homeostatic functions, including the regulation of
76 deep body temperature (Tb).
77 Supporting the role of PACAP38 in thermoregulation, the
78 peptide and its receptors are broadly expressed in main ther-
79 moregulatory areas of the brain, including the lateral
80 parabrachial area, the preoptic area of the hypothalamus
81 (POA), the dorsomedial nucleus of the hypothalamus, the
82 periaqueductal gray matter, and the nucleus raphe pallidus
83 (Palkovits et al. 1995; Joo et al. 2004; Das et al. 2007). In
84 physiological studies, the injection of PACAP38 into the
85 lateral cerebral ventricle (Pataki et al. 2000, 2003; Hawke
86 et al. 2009), the intrathecal space (Inglott et al. 2011), or onto
87 the ventromedial hypothalamic nucleus (Resch et al. 2011,
88 2013) caused an increase of Tb in rats and mice. Although
89 elevation of non-shivering thermogenesis (Hawke et al. 2009;
90 Inglott et al. 2011; Resch et al. 2011) and increase of locomo-
91 tor activity (Resch et al. 2011, 2013) have been shown to
92 contribute to the PACAP38-induced hyperthermia, no study
93 has yet been conducted to investigate simultaneous activation
94 of autonomic thermoeffectors.
95 The thermoregulatory system operates as a federation of
96 independent thermoeffector loops, in which each loop consists
97 of a sensor, an afferent, and an efferent branch (Romanovsky
98 2007a). For example, environmental cold activates cutaneous
99 cold receptors and signals from the skin are conveyed to
100 thermoregulatory centers in the brain from where autonomic
101 (thermogenesis, cutaneous vasonconstriction) and behavioral
102 (warmth seeking) cold-defense effectors are driven
103 (Romanovsky 2014). These defense mechanisms can be mod-
104 ulated from peripheral (Almeida et al. 2012) as well as from
105 central sites (Nakamura and Morrison 2008b). A substance
106 such as PACAP38 can act at any element of a thermoeffector
107 loop and cause the same effect: hyperthermia. Since the ther-
108 moregulatory response to PACAP38 has not been compared
109 between systemic (outside the blood–brain barrier) and central
110 (into CNS) substance delivery, it cannot be firmly stated
111 whether the primary site of action of PACAP38 is on periph-
112 eral afferents, in the brain as proposed by Resch et al. (2011,
113 2013), in the spinal cord as suggested by Inglott et al. (2011),
114 or on the efferent neural pathway of a thermoeffector (e.g.,
115 that of the brown adipose tissue).
116 In addition to exogenous PACAP38 administration, geneti-
117 cally modified mice lacking the Pacap gene have also been
118 utilized to investigate how the absence of PACAP affects deep
119Tb. These studies obtained contradictory results showing that
120the absence of PACAP in mice lead to increased (Hashimoto
121et al. 2001) versus unchanged locomotor activity (Adams et al.
1222008), as well as to lower (Hashimoto et al. 2009) versus
123unchanged Tb as compared to controls (Cummings et al. 2008).
124In the present study, we characterized the dose-dependency
125of and the autonomic thermoeffector pattern involved in the
126response to PACAP38. Then, in a comparative experiment,
127we addressed the question whether exogenous PACAP38
128administration acts primarily through peripheral or central
129targets in rats. Lastly, as an additional approach to identify
130the role of PACAP in thermoregulation, we used mice lacking
131the Pacap gene and studied how the absence of PACAP
132affects circadian changes of their deep Tb and locomotor
133activity as well as their basal Tb and metabolic rate.
134Materials and Methods
135Animals
136The physiological experiments were performed in 40 adult
137male Wistar rats and 42 adult mice of both sexes. The mice
138had the Pacap gene homozygously either present (Pacap+/+) or
139absent (Pacap−/−) due to a targeted disruption (Hashimoto et al.
1402001). Generation by a gene-targeting technique, maintenance,
141and backcrossing of Pacap−/− mice on a CD1 background has
142been reported previously (Hashimoto et al. 2001, 2009). Ani-
143mals were housed in temperature-controlled rooms on a 12 h
144light–dark cycle. Standard rodent chow and tap water were
145available ad libitum. At the time of the experiments, the rats
146weighed 331±33 g and the mice weighed 24±2 g.
147Rats and mice were extensively handled and then habitu-
148ated to staying inside wire-mesh cylindrical confiners. The
149cylindrical confiner prevented the animal from turning
150around, but allowed for some back-and-forth movements; it
151was used in the respirometry setup (see the “Experimental
152Setups” section below).
153All procedures were conducted under protocols approved
154by Institutional Animal Use and Care Committee of the Uni-
155versity of Pecs and were in accordance with the directives of
156the National Ethical Council for Animal Research and those of
157the European Communities Council (86/609/EEC).
158Surgeries
159Mice
160Mice were anesthetized with a ketamine–xylazine cocktail
161(81.7 and 9.3 mg/kg, respectively, i.p.) and received antibiotic
162protection (gentamycin, 6 mg/kg, i.m.). During surgery, a
163mouse was heated with a temperature-controlled heating pad
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164 (model TMP-5a; Supertech Instruments UK Ltd., London,
165 UK) placed under a surgery board.
166 A mouse designated for an experiment in the telemetry
167 setup was implanted with a miniature telemetry transmitter
168 (G2 E-Mitter series; Mini Mitter, Bend, OR, USA) to record
169 abdominal temperature (Tab, a measure of deep Tb) and loco-
170 motor activity. The device was inserted into the peritoneal
171 cavity via midline laparotomy and fixed to the lateral abdom-
172 inal wall (right side) with a suture. The surgical wound was
173 sutured in layers. After the surgery, mice were allowed to fully
174 recover for 10 days before data collection started.
175 Rats
176 Surgeries were performed under ketamine–xylazine (55.6 and
177 5.5 mg/kg, respectively, i.p.) anesthesia and antibiotic protec-
178 tion (gentamycin, 6 mg/kg, i.m.). Experiments were per-
179 formed 2 to 4 days after surgery. Each rat was implanted with
180 either an intravenous (i.v.) catheter or an intracerebroventric-
181 ular (i.c.v.) cannula as described below.
182 For i.v. catheter implantation, a small longitudinal incision
183 wasmade on the ventral surface of the neck, left of the trachea.
184 The left jugular vein was exposed, freed from its surrounding
185 connective tissue, and ligated. A silicone catheter (ID 0.5 mm,
186 OD 0.9 mm) filled with heparinized (10 U/ml) saline was
187 passed into the superior vena cava through the jugular vein
188 and secured in place with ligatures. The free end of the
189 catheter was knotted, tunneled under the skin to the nape,
190 and exteriorized. The wound was sutured. The catheter was
191 flushed with heparinized saline (10 U/ml) on the day
192 after the surgery and every other day. This technique
193 was repeatedly used in our earlier studies (Petervari
194 et al. 2005; Garami et al. 2010).
195 For i.c.v. cannulation, each rat was fixed to a stereotaxic
196 apparatus as carried out in our earlier studies (Petervari et al.
197 2009, 2010). The scalp was incised over the sagittal suture; the
198 periosteum was excised; the skull was cleaned and dried; two
199 supportingmicroscrewswere driven into the skull; and a small
200 hole was drilled in the skull 1.0 mm antero-posterior from
201 bregma and 1.5 mm lateral from midline. A 22-G steel guide
202 cannula was attached to a plastic tube fitted into a stereotaxic
203 manipulator (Narishige Scientific Instruments Laboratory, To-
204 kyo, Japan), which was used to insert the cannula into the
205 brain through the bone hole. The tip of the cannula was placed
206 within the right lateral ventricle (3.8 mm from dura). The
207 cannula was secured to the supporting microscrews with
208 dental cement and released from the manipulator. The guide
209 cannula was closed by a dummy cannula.
210 Experimental Setups
211 Physiological experiments in unanesthetized animals were
212 conducted in either the respirometry setup or the telemetry
213setup. The respirometry setup was used (a) to measure the
214thermoregulatory responses of rats to non-stressful adminis-
215tration of PACAP38 and (b) to assess the basal thermoregula-
216tory parameters of untreated, loosely restrained Pacap−/− and
217Pacap+/+ mice. The telemetry setup was used only in untreat-
218ed, freely-moving Pacap−/− and Pacap+/+ mice to record their
219Tab and locomotor activity over a longer period (24 h) of time.
220In the respirometry setup, a rat or mouse equipped with
221copper–constantan thermocouples (Omega Engineering,
222Stamford, CT, USA) to measure colonic (Tc), and tail skin
223temperature (Tsk) was placed in a confiner. The colonic ther-
224mocouple was inserted 10 or 3 cm beyond the anal sphincter
225in rats and mice, respectively, and fixed to the base of the tail
226with a loop of adhesive tape. The skin thermocouple was
227positioned on the lateral surface of the tail (at the boundary
228of the proximal and middle thirds) and insulated from the
229environment with tape. The thermocouples were plugged into
230a data logger (Cole-Parmer, Vernon Hills, IL, USA). Then,
231each animal in its confiner was transferred to a Plexiglas
232chamber of the four-chamber open-circuit calorimeter inte-
233grated system (Oxymax Equal Flow, Columbus Instruments,
234Columbus, OH, USA). The chamber was sealed, submerged
235into a temperature-controlled water bath, and continuously
236ventilated with room air (1,000 and 200 ml/min for rats and
237mice, respectively). The fractional concentration of oxygen
238was measured in the air entering and exiting the chamber, and
239the rate of oxygen consumption (VO2) was calculated accord-
240ing to the manufacturer’s instructions using the OxymaxWin-
241dows software (v3.1). When present, the venous catheter was
242connected to a polyethylene-50 extension filled with the drug
243of interest. When the animal had an i.c.v. cannula, a needle
244injector was fitted into the guide cannula and connected to a
245polyethylene extension (ID 0.28 mm, OD 0.61 mm). The
246extension was passed through a port of the chamber and
247connected to a syringe. All experiments were conducted at
248an ambient temperature (Ta) of 28.0 °C or 31.0 °C, which is
249thermoneutral for rats and mice, respectively, in this setup
250(Balasko et al. 2010; de Oliveira et al. 2014).
251In the telemetry setup, mice were studied inside their home
252cages. Telemetry receivers (model ER-4000; Mini Mitter)
253were positioned in a temperature-controlled room, and the
254home cages of mice were placed on top of the receivers. In
255this setup, a Ta of 27.0 °C was used, which is near the lower
256end of the thermoneutral zone for mice (Kanizsai et al. 2009).
257The mouse was preimplanted with a telemetry transmitter to
258measure Tab and locomotor activity. The latter has been shown
259to play an important thermoregulatory role in small rodents
260such as rats and mice (Mount andWillmott 1967; Brown et al.
2611991; Weinert and Waterhouse 1998). A similar method was
262also used to detect small differences in the thermoregulatory
263phenotype between transient receptor potential vanilloid-1
264(TRPV1) channel knockout and control mice (Kanizsai et al.
2652009; Garami et al. 2011).
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266 Substance Administration
267 PACAP38 was synthesized at the University of Szeged as
268 described in details elsewhere (Gasz et al. 2006). Lyophilized
269 aliquots of PACAP38 were stored at 4 °C. On the day of the
270 experiment, an aliquot was dissolved in saline to give a
271 working solution of PACAP38 at 0.3, 0.6, or 6 mg/ml. For
272 the i.v. drug administration, the 0.3 mg/ml working solution
273 was infused to rats at a rate of 87 μl/min/kg (~29 μl/min/rat)
274 for 4 min to deliver a final dose of PACAP38 at 100 μg/kg
275 (~33 μg/rat). For i.c.v. drug administration, 5 μl of the 0.6 or
276 6 mg/ml working solutions were infused over a 3-min time
277 period to deliver PACAP38 at doses of 10 and 100 μg/kg
278 (~3.3 and 33 μg/rat), respectively. Control animals were in-
279 fused with saline.
280 Immunocytochemistry for c-Fos
281 The labeling was performed as published earlier
282 (Gaszner et al. 2012). Briefly, Pacap−/− and Pacap+/+
283 mice were injected within a time period of 2 min with
284 i.p. administered Nembutal (sodium-pentobarbital;
285 100 mg/kg body weight; Sanofi, Budapest, Hungary).
286 All mice became unconscious within 2 min. Then, they
287 were transcardially perfused with 25 ml of 0.1 M sodi-
288 um phosphate-buffered saline (PBS; pH 7.4) for 2 min,
289 followed by perfusion with 150 ml of ice-cold 4 %
290 paraformaldehyde in 0.2 M Millonig sodium phosphate
291 buffer (pH 7.4), for 20 min. Brains were removed and
292 post-fixed for 24 h. Coronal sections (30 μm) were
293 prepared on vibratome (Lancer, Ted Pella Inc., Redding,
294 CA, USA) and stored in anti-freeze solution at−20 °C.
295 For free-floating diaminobenzidine (DAB; Sigma Chem-
296 ical, Zwijndrecht, The Netherlands) immunocytochemis-
297 try, sections were washed 6×10 min in 0.1 M PBS.
298 Consecutively, sections were incubated in 0.5 % Triton
299 X-100 (Sigma Chemical), then in a blocking buffer of
300 2 % normal goat serum (NGS, Jackson Immunoresearch
301 Europe Ltd., Suffolk, UK) in PBS for 30 min. Sections
302 were transferred into an antiserum solution (1:500)
303 raised against c-Fos (Santa Cruz Biotechnology Inc.,
304 sc-52, Santa Cruz, CA, USA). After 3×10 min washes,
305 sections were treated with biotinylated goat anti-rabbit
306 IgG, (1:200) containing 2 % NGS, for 2 h at 20 °C.
307 After a rinse in cold PBS, sections were placed into
308 avidin–biotin-complex solution (Vectastain Elite ABC
309 Kit, Vector Laboratories, Burlingame, CA, USA), for
310 1 h at 20 °C, followed by PBS for 3×10 min washes.
311 The immunoreaction was visualized using 0.02 % DAB
312 in Tris buffer with 0.00003 % H2O2, for 10 min. The
313 reaction was observed under microscope and stopped
314 with PBS. After washes, sections were mounted on
315 gelatin-coated slides, dried, cleared by 2×10 min xylene
316treatment, coverslipped with DePex (Fluka, Heidelberg,
317Germany), and studied with a Nikon Microphot FXA
318microscope and Spot RT color digital camera (Nikon,
319Tokyo, Japan).
320The polyclonal c-Fos antiserum (Santa Cruz Biotechnolo-
321gy Inc., sc-52, Santa Cruz, CA, USA) had been generated
322against the 3–16 amino acid c-Fos peptide fragment of
323human origin. Preadsorption with 0.1, 1, and 10 μg
324synthetic c-Fos blocking peptide (Santa Cruz Biotech-
325nology Inc., sc-52 P, Santa Cruz, CA, USA); moreover,
326omission or replacement of the c-Fos serum by nonim-
327mune rabbit serum effectively prevented the staining.
328The cross reactivity of this antiserum with other Fos-
329related proteins was excluded earlier by Ryabinin et al.
330(1999). Western blot analysis support the specificity of
331the antibody used (for details see supplier’s web site:
332http://http://datasheets.scbt.com/sc-52.pdf).
333Microscopy, Digital Imaging, and Morphometry
334Per animal, the cell counts positive for c-Fos were
335determined in five serial sections, each interspaced by
33660 μm in the median preoptic nucleus (MnPO) and
337medial preoptic area (MPO) according to Paxinos and
338Franklin (2004) atlas. Cell counting was carried out on
339non-edited digital images using ImageJ software (ver-
340sion 1.37, NIH, Bethesda, MD, USA). Quantitation was
341performed in a double-blind setup by a colleague who
342is an expert in the rodent neuroanatomy, but was
343blinded to the identity of preparations. Two representa-
344tive digital images were grayscaled and contrasted using
345Photoshop software (Adobe, San Jose, CA, USA) for
346publication purposes.
347Data Processing and Analysis
348Data on Tc, Tab, heat loss index (HLI), and VO2 were
349compared by two-way ANOVA followed by Fisher’s
350LSD post hoc tests, as appropriate. The HLI was calcu-
351lated as:
HLI ¼ Tsk − Ta
Tc−Ta
:
3523
354The HLI changes between 0 (maximum heat conser-
355vation due to skin vasoconstriction) and 1 (theoretical
356maximum heat loss due to skin vasodi la t ion;
357Romanovsky et al. 2002). Numbers of the c-Fos-
358positive cells were compared by Student’s two sample
359t test (alpha = 5 %). For statistical analysis, Sigmaplot
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360 11.0 (Systat Software, San Jose, CA, USA) software
361 was used. All data are reported as mean±SE.
362
363 Results
364 Characteristics of the Thermoregulatory Response to Central
365 (i.c.v.) PACAP38 Administration
366 To characterize the thermoregulatory effect of PACAP38 in
367 details, we infused 10 or 100 μg/kg of the peptide (or saline)
368 into the lateral cerebral ventricle of rats and recorded their Tc,
369 Tsk, and VO2 in the respirometry setup. In all rats studied,
370 infusion of saline did not have any influence on Tc, HLI, and
371 VO2 (Fig. 1). On the contrary, both of the applied doses of
372 PACAP38 caused a marked rise in the Tc starting already at
373 10 min after the injection (p<0.001 for both; Fig. 1). The
374 magnitude of the PACAP38-induced hyperthermia was dose-
375 dependent with a maximal Tc change of 2.0±0.3 °C and 1.4±
376 0.3 °C at the dose of 100 and 10 μg/kg, respectively (p<0.001
377 for both). Statistical analysis also revealed significant differ-
378 ence (p<0.001) between the effects of the 10 vs. 100 μg/kg
379 dose of PACAP38 on Tc. The hyperthermic response to
380intrabrain administration of PACAP38 is in harmony with
381earlier reports on the effect of PACAP38 injection on Tb in
382rats (Pataki et al. 2000, 2003; Resch et al. 2011, 2013).
383In the case of the 100 μg/kg dose, the development of the
384hyperthermia was preceded by significant tail skin vasocon-
385striction (as indicated by a decreased HLI; p<0.05). This is a
386novel finding of our study, and to our knowledge, the first to
387report cutaneous vasomotor responses to i.c.v. PACAP38 in
388conscious rats. It indicates that the thermoregulatory
389(constrictor) effect of PACAP38 on the cutaneous vascular
390tone is different from its direct (dilator) effect on skin vessels,
391which was shown earlier in small rodents (Absood et al. 1992;
392Tsueshita et al. 2002). The initial drop of HLI lasted for
393~40 min, and then, it was followed by a pronounced elevation
394of HLI due to tail skin vasodilation, which remained signifi-
395cantly (p<0.05) higher than theHLI of saline-treated rats until
396the end of the experiment in accordance with the vasodilatory
397effect of PACAP38 reported earlier (Absood et al. 1992;
398Tsueshita et al. 2002). Rats treated with 10 μg/kg PACAP38
399i.c.v. had low HLI already before substance administration;
400thus, the initial drop of HLI in this group could not be ob-
401served, however, ~50 min after drug infusion HLI increased
402above baseline levels and became higher than that of controls
403(p<0.05), although the magnitude and the duration of HLI
404elevation were smaller than those observed at 100 μg/kg.
405Similarly to Tc, the VO2 of the rats increased already at
40610 min after i.c.v. PACAP38 administration as compared to
407saline-treated animals in a dose-dependent manner. It reached
408a maximal rise of 21±6 and 14±6 ml/kg/min at 100 and
40910 μg/kg, respectively (p<0.001 for both). This finding is in
410harmony with previous studies, in which PACAP38 elevated
411the metabolic rate (Hawke et al. 2009; Inglott et al. 2011;
412Resch et al. 2011). In addition, our results demonstrate that
413simultaneous immediate activation of both autonomic cold-
414defense thermoeffectors (cutaneous vasoconstriction and
415brown adipose tissue thermogenesis) contribute to the devel-
416opment of hyperthermia in response to PACAP38.
417Investigation of the Thermoregulatory Response to Systemic
418(i.v.) PACAP38 Administration
419The dose-dependent hyperthermia in response to PACAP38
420injection either into the lateral ventricle (current study; Pataki
421et al. 2000, 2003) or into the hypothalamus (Resch et al. 2011,
4222013) suggests that the site of action for PACAP38 is located
423in the CNS, but one can not rule out the possibility that
424intrabrain PACAP38 administration acts on central elements
425of a thermoregulatory loop, which receives its afferentation
426from the periphery and through central neural structures in-
427nervates the corresponding thermoeffector. Such scenario is
428plausible based on the modern concept of thermoregulation,
429according to which deep Tb is controlled by a federation of
430independent loops of thermoeffectors (for review, see
Q2 Fig. 1 Thermoeffector and Tc responses of rats to different doses (10 and
100μg/kg) of PACAP38 or saline administered i.c.v. The changes of Tc (a
measure of deep Tb) are shown in the upper panel; alterations in the
activity of the two main autonomic thermoeffectors, HLI and VO2, are
depicted in the middle and lower panel, respectively. These experiments
were performed in the respirometry setup at a Ta of 28 °C. Numbers of
animals in the corresponding groups are indicated in the figure
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431 Romanovsky 2007b). In such a loop, activation of the
432 afferent pathway upstream from the central nuclei can
433 evoke equal effects as its activation at any, for example
434 central, part of the loop.
435 To study the possibility of a peripheral site of action for
436 PACAP38 in a comparative experiment, we investigated
437 whether the same (100 μg/kg) dose of PACAP38 that caused
438 pronounced hyperthermia when injected i.c.v. has a similar
439 effect on deep Tb in the case of a systemic (i.v.) administration.
440 Infusion of saline did not have thermoregulatory effects in the
441 rats studied (Fig. 2). When PACAP38 at 100 μg/kg was
442 infused i.v., it caused a slight, but significant (p<0.05) rise
443 of Tc. Both the maximum Tc elevation (~0.3 °C) and the
444 duration (60 min) of the hyperthermic response to systemic
445 PACAP38 infusion were markedly less than what i.c.v. ad-
446 ministration of the same dose evoked (p<0.05). One can argue
447 that neurons in the CNS were exposed to higher local concen-
448 trations of PACAP38 than neurons on the periphery after
449 infusion of the same dose into the two compartments, but
450 the differences in local concentrations are unlikely to account
451 for the substantial differences observed in the Tc response.
452 Importantly, the response to PACAP38 at 100 μg/kg i.v. was
453 substantially smaller both in magnitude (~5-fold lesser) and in
454 duration (~2 times shorter) than the effect of a tenfold smaller
455 dose (10 μg/kg) delivered i.c.v. (Fig. 1). Similarly to what we
456 observed after i.c.v. drug delivery, in the case of the i.v.
457 infusion of PACAP38, the hyperthermia was also brought
458about by a decreased heat loss and an increased VO2, although
459activity of both thermoeffectors changed to a much lesser
460extent than after i.c.v. delivery (Fig. 2). The result that even
461a tenfold lower dose of PACAP38 caused much stronger
462hyperthermia after i.c.v. administration compared to i.v.
463delivery, unequivocally shows that the site of action for
464the thermoregulatory response to PACAP38 is situated
465within the CNS.
466Thermoregulatory Characteristics of Pacap−/− Mice
467After we characterized the thermoregulatory response to ex-
468ogenous PACAP38 administration, we wanted to know how
469the absence of PACAP affects deep Tb.
470First, we studied the circadian changes of Tab and locomo-
471tor activity in freely moving Pacap−/− and Pacap+/+ mice
472(Fig. 3a). Representing the characteristic circadian rhythm of
473rodents, mice of both genotypes had lower Tab and activity
474levels during the light (inactive) phase than during the dark
475(active) phase. In accordance with the study by Hashimoto
476et al. (2001), we found that Pacap−/− mice were more active
477than their wild-type littermates during both the light and the
478dark phase of the day (p<0.001). During most of the light
479phase (between 5 a.m. and 3 p.m.), the increased locomotor
480activity resulted in a moderately higher Tab in the Pacap
−/−
481mice compared to controls (p<0.05); but in the night, there
482was no significant difference in Tab between the genotypes
483(Fig. 3a). Similar results on the effect of hyperactivity on deep
484Tb were also demonstrated in chicken (Aschoff and von Saint-
485Paul 1973) and inmice (Weinert andWaterhouse 1998, 1999),
486showing that elevated locomotor activity resulted in higher Tb
487during the inactive phase, but not during the active phase. It
488can be assumed that the different light–dark influence of
489locomotor activity on deep Tb can originate from the circadian
490changes of cutaneous vasodilation, thus heat loss mechanisms
491(Weinert and Waterhouse 1998).
492Next, we measured the basal Tc and VO2 in loosely re-
493strained Pacap−/− and Pacap+/+ mice (Fig. 3b). These exper-
494iments were performed in the respirometry setup (see the
495“Materials and Methods” section), so we could minimize the
496influence of locomotor activity on Tc and VO2. We recorded
497the basal thermoregulatory parameters for 60 min starting
498from 11 a.m. because this time period corresponded to the
499biggest difference in deep Tb between freely moving Pacap
−/−
500and Pacap+/+ mice (Fig. 3a). As shown in Fig. 3b, the basal
501VO2 was significantly lower in Pacap
−/− mice as compared to
502controls throughout the experiment (p<0.001). As a conse-
503quence of their hypometabolism, Tc of the Pacap
−/−mice was
504also slightly lower than that of controls (p<0.01).
505To assess which neurons are responsible for maintaining
506the reduced resting metabolic rate in Pacap−/− mice, we mea-
507sured expression of the inducible transcription factor c-Fos, a
508marker of neuronal activation (Sagar et al. 1988), in theMnPO
Fig. 2 The thermoregulatory response of rats to PACAP38 (100 μg/kg)
or saline administered i.v. Changes of Tc (upper panel), HLI (middle
panel), and VO2 (bottom panel) are shown with the same scale intervals
as in Fig. 1. The experimental conditions were also identical to those
described in Fig. 1 (respirometry setup, Ta of 28 °C). Numbers of animals
in the corresponding groups are indicated in the figure
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509 and MPO (Fig. 4a). It is well established that neurons in these
510 brain areas are involved in the regulation of thermogenesis
511 (Nakamura andMorrison 2008b; Romanovsky et al. 2009). In
512 the MnPO, we found no statistical difference in the number of
513 c-Fos-positive cells between Pacap−/− and Pacap+/+ mice;
514 however, c-Fos expression was nearly three times higher
515 (p<0.05) in the MPO of the Pacap−/− mice as compared to
516 their wild-type littermates (Fig. 4b). It has been shown that
517 GABAergic neurons in the MPO tonically suppress BAT
518 thermogenesis (Osaka 2004) and can be regarded as the first
519 effector neurons of the thermoregulatory loops controlling
520 autonomic thermoeffectors (Romanovsky et al. 2009), there-
521 fore, our current findings in Pacap−/− mice suggest that the
522 absence of PACAP results in an increased activation of the
523inhibitoryMPO neurons leading tomore pronounced suppres-
524sion of thermogenesis.
525
526Discussion
527Our findings clearly demonstrate that central, rather than
528peripheral mechanisms are involved in the hyperthermia-
529inducing effect of PACAP38. Although PACAP38-induced
530hyperthermia has been studied earlier in small rodents, based
531on data currently available from those experiments, no firm
532conclusion could be drawn about the site of the thermoregu-
533latory action of PACAP38. In previous studies, PACAP38was
534administered only into the CNS (Pataki et al. 2000, 2003;
535Hawke et al. 2009; Inglott et al. 2011; Resch et al. 2011,
5362013) and evoked prominent thermoregulatory responses,
537suggesting a central mediation of the effect. However, taken
538into account the organization of the thermoregulatory system,
539which consists of independently operating thermoeffector
540loops (Romanovsky 2007a, b), the interpretation of the results
541obtained with one single injection of a substance into the CNS
542can be misleading, because it can not be excluded that activa-
543tion of an upstream or downstream peripheral structure of the
544same thermoregulatory pathway could cause the same or
Fig. 3 The thermoregulatory phenotype of Pacap−/− and Pacap+/+ mice.
a Circadian changes of Tab and locomotor activity in freely moving
Pacap−/− and Pacap+/+ mice. These experiments were performed in the
telemetry setup at a Ta of 27 °C. b Basal Tc and VO2 of loosely restrained
Pacap−/− and Pacap+/+ mice. Recordings of Tc and VO2 were performed
between 11 a.m. and 12 p.m. in the respirometry setup at a Ta of 31 °C.
Numbers of animals in the corresponding groups are indicated in the
figure
Fig. 4 The expression of c-Fos positive cells in the MnPO and MPO of
Pacap−/− and Pacap+/+ mice. a Schematic drawing from Paxinos and
Watson Q3(2004) atlas and representative photomicrographs of coronal
sections from the MnPO and MPO at the anterior–posterior coordinate
of 0.14 mm from Bregma. The anterior commissure (ac) and the third
ventricle (3 V) are shown as landmarks. b Quantitative analyses of c-Fos
immunoreactive cells in the MnPO and MPO. Numbers of animals in the
corresponding groups are indicated in the figure
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545 similar effect. For example, Inglott et al. (2011) found that
546 i n t r a t h e c a l l y a dm i n i s t e r e d PACAP38 e x e r t s
547 sympathoexcitation even after spinal transection and the
548 authors concluded that the effect is, therefore, evoked from
549 the spinal cord itself. Based on the functional architecture of
550 the thermoregulatory system, however, the results by Inglott
551 et al. (2011) can also be explained by a direct effect of
552 PACAP38 on efferent spinal structures (most likely the
553 intermediolateral column) of the same thermoregulatory loop,
554 which can be also activated upstream in the brain by i.c.v.
555 (current s tudy; Pataki et al . 2000, 2003) or by
556 intrahypothalamic infusions (Resch et al. 2011, 2013) and
557 the activation of which leads to equivalent effects regardless
558 of the order of the neuron being activated in the loop.
559 Supporting a peripheral site of action, PACAP38 and its
560 receptor have been shown to be widely expressed on sensory
561 neurons in the periphery (for review, see Mulder et al. 1999;
562 Vaudry et al. 2000) and in the enteric nervous system
563 (Miampamba et al. 2002). In the present study, we compared
564 the effects of central and systemic administration, and showed
565 that the same or even a tenfold lower dose of PACAP38
566 evokes stronger hyperthermia, when given i.c.v. than when
567 delivered i.v. This result unequivocally supports the central
568 mediation hypothesis. The slight increase of Tc in response to
569 peripherally infused PACAP38 could be attributed to its pen-
570 etration of the blood–brain barrier (Banks et al. 1993; Nonaka
571 et al. 2002). To our knowledge, this is the first report in
572 which the central and peripheral thermoregulatory re-
573 sponses to PACAP38 were compared under identical
574 experimental conditions.
575 We also studied the characteristics of the thermoregulatory
576 response to PACAP38 and found that the hyperthermia started
577 to develop promptly: already 10min after drug administration,
578 we could detect the activation of thermoeffectors and a slight
579 increase of Tc. This is a novel finding of the study as in all of
580 the earlier studies investigating the thermal effect of
581 PACAP38, Tb was recorded hourly and the substance was
582 administered in a stressful manner, thus the developing
583 stress-induced hyperthermia, which was also present in the
584 vehicle-treated animals masked the early phase of the re-
585 sponse. We found that PACAP38 administration resulted in
586 the simultaneous activation of non-shivering thermogenesis
587 and cutaneous vasoconstriction, which are the two principal
588 autonomic cold-defense thermoeffectors (Romanovsky
589 2007a). It has to be noted that the measured increase in VO2
590 can theoretically originate from elevation of both shivering
591 and non-shivering thermogenesis; but in small rodents, non-
592 shivering thermogenesis is the primary source of heat produc-
593 tion (for review, see Cannon and Nedergaard 2004). The
594 initial skin vasoconstriction seems to contradict the reported
595 vasodilatory effect of PACAP38 (Absood et al. 1992;
596 Tsueshita et al. 2002), but this contradiction can be resolved
597 by considering that in the current study PACAP38 was
598delivered into the lateral ventricle of the brain, from where it
599can broadly access the POA, where neurons of the
600thermoeffector pathway for tail skin vasomotor tone are situ-
601ated (Nakamura and Morrison 2008a, b). Therefore, it is
602plausible that PACAP38 acted on central thermoregulatory
603elements resulting in skin vasoconstriction, but when the
604peptide spread to more distant (non-thermoregulatory) areas,
605it caused vasodilatory effect, which was also observed in the
606current study ~40 min after PACAP38 injection (Fig. 1).
607Although the later occurring cutaneous vasodilation lasted
608longer than the initial skin vasonconstriction, from a thermo-
609regulatory point of view, the initial decrease of heat loss is
610equally important, as it was present during the developmental
611phase of PACAP38-induced hyperthermia, thus contributed to
612the rise of deep Tb.
613Since neurons of the thermoeffector loop for non-shivering
614thermogenesis are also located in the POA (for review, see
615Romanovsky et al. 2009), it is tempting to assume that the site
616of the hyperthermic effect of PACAP38 is in the POA on
617neurons, which belong to the common part of the
618thermoeffector pathways for non-shivering thermogenesis
619and cutaneous vasoconstriction. Supporting this hypothesis,
620the PAC1 receptor, which has been shown to be involved in
621mediation of the hyperthermic effect of PACAP38 (Tachibana
622et al. 2007; Resch et al. 2013), is abundantly expressed in the
623MnPO of the POA (Joo et al. 2004), where GABAergic
624neurons controlling autonomic cold-defense thermoeffectors
625can be found (Nakamura and Morrison 2008a). In recent
626studies from Resch et al. (2011, 2013), it has been proposed
627that the hyperthermic and hypermetabolic effects of
628PACAP38 are mediated by neurons in the hypothalamic ven-
629tromedial nucleus and possibly in the lateral parabrachial
630nucleus. Our hypothesis is also in harmony with these results,
631because in the cold-activated pathway glutamatergic neurons
632from the lateral parabrachial nucleus project to GABAergic
633neurons in the MnPO (Nakamura and Morrison 2008b),
634which in turn, are connected to neurons of the hypothalamic
635ventromedial nucleus (Imai-Matsumura et al. 1988; Thornhill
636et al. 1994).
637As an alternative approach to study the role of PACAP in
638thermoregulation, we investigated deep Tb and locomotor
639activity of Pacap−/− mice and found that these mice were
640hyperactive throughout the day and hyperthermic during the
641light phase as compared to controls. The hyperactivity of
642Pacap−/− mice was also observed in an earlier study
643(Hashimoto et al. 2001) and, although Adams et al. (2008)
644reported no alteration in the locomotor activity of the Pacap−/−
645mice compared to controls, in their study during the three
646consecutive nights of the experiments the number of beam
647breaks in case of the Pacap−/− mice exceeded by ~2,000 (i.e.,
648by ~50 %) that of controls at certain time points. It is a novel
649finding of the present study that in our experiments, the
650increased activity of the Pacap−/− mice resulted in elevated
J Mol Neurosci
JrnlID 12031_ArtID 361_Proof# 1 - 27/06/2014
AUTHOR'S PROOF
U
N
C
O
R
R
EC
TE
D
PR
O
O
F
651 Tb during the light phase of the day, in which phase locomotor
652 activity correlates strongly with Tb (Weinert and Waterhouse
653 1998, 1999). In contrast to our findings, in the study by
654 Hashimoto et al. (2009) Pacap−/− mice had lower Tb during
655 the night than controls, but those experiments were conducted
656 at a Ta of 23 °C, which could be presumably below the
657 thermoneutral zone of mice. As it has been repeatedly shown
658 that cold-defense responses of Pacap−/− mice are impaired
659 compared with controls (Gray et al. 2002; Adams et al. 2008;
660 Cummings et al. 2008), it can be assumed that the different
661 influence of a chronic, mild cold exposure on the Tb of
662 Pacap−/− and Pacap+/+ mice could contribute to the observed
663 lower Tb in the Pacap
−/− mice. Indeed, inadequate heat pro-
664 duction and lower Tb in Pacap
−/− mice were observed in
665 response to chronic, mild (21 °C) cold exposure in the study
666 by Gray et al. (2002). In an earlier study by Cummings et al.
667 (2008), the Tb of Pacap
−/− mice did not significantly differ
668 from that of controls, however, in that study the authors
669 measured rectal temperature in previously decapitated mice,
670 which method is not sensitive enough to detect small (espe-
671 cially locomotion-induced) differences in Tb. Locomotor ac-
672 tivity is widely viewed as a thermoregulatory effector in mice
673 (Kanizsai et al. 2009; Szentirmai et al. 2010; Garami et al.
674 2011) and our findings suggest that freely moving Pacap−/−
675 mice utilize locomotor activity as a thermoeffector to maintain
676 an elevated Tb during the light phase and normal Tb during the
677 night phase of the day. It has to be mentioned that the
678 increased locomotor activity of the Pacap−/− mice could pos-
679 sibly also originate from distinct mechanisms, which are
680 independent from thermoregulation.
681 We then asked whether the basal daytime Tb of loosely
682 restrained Pacap−/− mice (i.e., those that can not use locomo-
683 tion as a thermoeffector) also differs from their wild-type
684 littermates. In contrast to our results in freely moving mice,
685 when restrained, Pacap−/− mice were hypometabolic and had
686 lower Tb than controls. The decreased metabolic rate and Tb in
687 the absence of PACAP is in harmony with our results demon-
688 strating the hypermetabolic and hyperthermic effect of
689 PACAP38 injection in rats. Whenwemeasured the expression
690 of c-Fos positive cells in the POA of the mice, we found that
691 the number of c-Fos positive cells in the MPO was markedly
692 higher in Pacap−/− mice than in controls, suggesting that the
693 absence of PACAP results in an increased activation of MPO
694 neurons. Since GABAergic neurons in the MPO tonically
695 suppress thermogenesis (Osaka 2004), we propose that in
696 Pacap−/− mice inhibitory MPO neurons are more activated
697 and this results in an enhanced suppression of thermogenesis.
698 This hypothesis is also in harmony with the proposed action of
699 PACAP38 injection on GABAergic MnPO neurons (see
700 above), because activation of these neurons results in an
701 increased inhibition of the inhibitory MPO neurons, which
702 leads to elevated metabolic rate and hyperthermia. Although
703 alternate explanations are also plausible, it can be assumed
704that the absence of PACAP38 results in a lower resting met-
705abolic rate (and Tb) and as a compensatory mechanism for the
706hypometabolism, Pacap−/− mice become hyperkinetic to
707maintain normal (or even higher) Tb. Interestingly, a similarly
708altered thermoeffector pattern (hypometabolism and hyperki-
709nesis) was observed in our recent study with mice lacking the
710TRPV1 channel (Garami et al. 2011). The similar thermoreg-
711ulatory consequences of the absence of PACAP and TRPV1
712can be explained with the alteration of the same neural path-
713ways as PACAP38 is released from activated capsaicin-
714sensitive (i.e., TRPV1-expressing) neural afferents into the
715systemic circulation (Helyes et al. 2007). Although the exact
716molecular and neuronal mechanisms involved in the develop-
717ment of the observed thermoregulatory phenotype ofPacap−/−
718mice need to be further investigated, an involvement of altered
719biochemical processes in the CNS of Pacap−/− mice can be
720suspected (Maasz et al. 2014).
721In conclusion, we showed in a straightforward comparative
722experiment that PACAP38 causes hyperthermia by acting on
723targets within the CNS. The PACAP38-induced hyperthermia
724is brought about through the simultaneous activation of both
725autonomic cold-defense effectors: elevation of non-shivering
726thermogenesis and cutaneous vasoconstriction. We hypothe-
727size that GABAergic neurons within the MnPO are involved
728in mediation of thermoregulatory response to PACAP38. The
729absence of PACAP results in hyperkinesis and daytime hy-
730perthermia in freely-moving Pacap−/− mice through mecha-
731nisms which need to be clarified, but an involvement of
732TRPV1 and altered central biochemical processes can be
733suspected. The increased locomotor activity is presumably a
734compensatory mechanism for the hypometabolism and hypo-
735thermia, which is present under resting conditions in the
736absence of PACAP.
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